Y. Furuya

ORCID: 0000-0002-7872-3474
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Transplantation: Methods and Outcomes
  • Renal Transplantation Outcomes and Treatments
  • Organ Transplantation Techniques and Outcomes
  • Prostate Cancer Treatment and Research
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Polyomavirus and related diseases
  • Organ and Tissue Transplantation Research
  • Mechanical Circulatory Support Devices
  • Pulmonary Hypertension Research and Treatments
  • Cancer, Lipids, and Metabolism
  • Pharmacological Receptor Mechanisms and Effects
  • Respiratory Support and Mechanisms
  • Pediatric Pain Management Techniques
  • Sinusitis and nasal conditions
  • Sepsis Diagnosis and Treatment
  • Cannabis and Cannabinoid Research
  • Pediatric health and respiratory diseases
  • Bladder and Urothelial Cancer Treatments
  • Medicinal Plant Research
  • Connective Tissue Growth Factor Research
  • Forensic Toxicology and Drug Analysis
  • Piperaceae Chemical and Biological Studies
  • Pharmacological Effects and Assays
  • Chronic Lymphocytic Leukemia Research
  • Lymphatic System and Diseases

PAX Scientific (United States)
2023-2024

Washington University in St. Louis
2016-2019

Hoshi University
2019

Ebara (Japan)
2019

Temple University
2014

Temple University Hospital
2014

Chiba University Hospital
2012

Keio University
2010

Tohoku Medical and Pharmaceutical University
2002

Teikyo University
2002

We examined the effect of alemtuzumab and basiliximab induction therapy on patient survival freedom from bronchiolitis obliterans syndrome (BOS) in double lung transplantation. The United Network for Organ Sharing database was reviewed adult transplant recipients 2006 to 2013. primary outcome risk-adjusted all-cause mortality. Secondary outcomes included time BOS. There were 6117 patients identified, whom 738 received alemtuzumab, 2804 basiliximab, 2575 no induction. Alemtuzumab had higher...

10.1111/ajt.13739 article EN cc-by-nc-nd American Journal of Transplantation 2016-02-02

Obliterative bronchiolitis (OB) is a poorly understood airway disease characterized by the generation of fibrotic bronchiolar occlusions. In lung transplant setting, OB pathological manifestation obliterans syndrome (BOS), which major impediment to long-term recipient survival. Club cells play key role in epithelial repair, but whether they promote tolerance through preventing remains unclear. We determined if occurs mouse orthotopic transplants following conditional transgene-targeted club...

10.1172/jci.insight.124732 article EN JCI Insight 2019-04-16

Donor-derived cell-free DNA (dd-cfDNA%) is a biomarker of early acute lung allograft dysfunction (ALAD), with value ≥1.0% indicating injury. Whether dd-cfDNA% useful in patients >2 y posttransplant unknown. Our group previously demonstrated that median recipients ≥2 without ALAD was 0.45%. In cohort, biologic variability estimated by reference change (RCV) 73%, suggesting exceeding 73% may be pathologic. this study, we aimed to determine whether or absolute thresholds are optimal for detecting ALAD.

10.1097/txd.0000000000001487 article EN cc-by-nc-nd Transplantation Direct 2023-05-24

E-2078 is a very stable dynorphin analog that has the same affinity and selectivity for opioid receptors as dynorphin-A by in vitro bioassay. In present study, we have characterized receptor of mu-, delta- kappa-representative binding assays, evaluated analgesic effect systemically administered tail pinch, flick formalin tests mice. possessed higher kappa-receptors than mu- or delta-receptors receptor-binding assay. Dose-related, long-lasting analgesia was produced s.c. injection E-2078, its...

10.1016/s0022-3565(25)20187-2 article EN Journal of Pharmacology and Experimental Therapeutics 1990-03-01

To evaluate the effects of i.v. CYC on number circulating endothelial progenitor cells (EPCs) in patients with SSc, and potential association EPC response CYC's effect for treating interstitial lung disease (ILD).This open-label, prospective study involved 12 SSc alveolitis (CYC group). All received six courses (0.5 g/m2) at 4-week intervals combination low-dose prednisolone. Ten were followed 24 months. Seven treated prednisolone alone used as a control measurement (control Five non-SSc CTD...

10.1093/rheumatology/keq259 article EN Lara D. Veeken 2010-08-19

A 71-year-old woman was admitted to our hospital in October 2009 with a 3-month history of severe diarrhea and weight loss 5 kg hypoalbuminemia. Computed tomography showed diffusely thickened small-intestinal wall intra-abdominal lymphadenopathy. Capsule endoscopy revealed flattened villi throughout the small intestine ([Fig. 1]). Double-balloon enteroscopy confirmed atrophic clearly visible Peyer's patches 2]). No neoplastic changes were observed on hematoxylin eosin staining mucosa, but...

10.1055/s-0030-1257081 article EN Endoscopy 2012-03-06

Introduction: Outcomes after induction immunosuppression in heart transplant patients have not been investigated since the allocation policy was changed 2006. The optimal therapy continues to be controversial with many centers continuing use none at all. We evaluated outcomes modern agents primary end points being survival and rejection. Methods: United Network for Organ Sharing (UNOS) database examined all transplants from January 2006 December 2012. Patients receiving were compared those...

10.1161/circ.132.suppl_3.18653 article EN Circulation 2015-11-10
Coming Soon ...